180
Participants
Start Date
November 27, 2008
Primary Completion Date
March 9, 2012
Study Completion Date
April 23, 2021
Volasertib
Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
Cytarabine
Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Brussels - UNIV Saint-Luc, Brussels
UZ Leuven, Leuven
AZ Sint-Jan Brugge, Bruges
LKH-Univ. Hospital Graz, Graz
Campus Virchow-Klinikum, Berlin, Berlin
HOP Clémenceau, Hémato, Caen, Caen
ASST Grande Ospedale Metropolitano Niguarda, Milan
Universitätsklinikum Hamburg-Eppendorf, Hamburg
Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel
A.O. Spedali Civili di Brescia, Brescia
Azienda Ospedaliera Policlinico di Modena, Modena
Universitätsklinikum Münster, Münster
Universitätsklinikum Frankfurt, Frankfurt am Main
Universitätsklinikum Heidelberg, Heidelberg
HOP Edouard Herriot, Lyon
HOP Saint-Louis, Paris
CTR Henri Becquerel, Rouen
Universitätsklinikum Freiburg, Freiburg im Breisgau
HOP Dupuytren 1, Limoges
Universitätsklinikum Ulm, Ulm
HOP, Centre Hospitalier René Dubos, Hémato, Paris, Cergy-Pontoise
Princess Margaret Cancer Centre, Toronto
Montreal General Hospital - McGill University Health Centre, Montreal
CHUS Fleurimont, Sherbrooke
CTR, fondation Paschetta, Hémato, Nice, Nice
Haukeland Universitetssykehus, Bergen
Oslo Universitetssykehus HF, Ullevål sykehus, Oslo
Lead Sponsor
Boehringer Ingelheim
INDUSTRY